CHARLOTTE, North Carolina (GenomeWeb) – T2 Biosystems this week presented data at the Association for Molecular Pathology meeting on the cost savings associated with its T2Candida sepsis panel.

The T2Candida panel — which can take a clinician from sample to result in around four hours — can not only improve patient care but can dramatically reduce costs associated with hospital stay times and antifungal therapies, John McDonough, CEO of T2 Biosystems, told an audience at AMP.